Editorial comment. A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma

European Journal of Cardio-thoracic Surgery

Volumn 31, Issue 3, 2007, Pages 534-535

  Rusch, Valerie W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DECORTICATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT PLANNING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; MESOTHELIOMA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NOTE; PHASE 2 CLINICAL TRIAL; PLEURA; PLEURA TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; HUMANS; INTERLEUKIN-2; MESOTHELIOMA; PLEURA; PLEURAL NEOPLASMS; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN;

EID: 33847304106     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.01.011     Document Type: Article

References (16)

1. Lucchi M., Chella A., Melfi F., Dini P., Ambrogi M., Fino L., Fontanini G., and Mussi A. A phase II study of intrapleural immuno-chemotherapy pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. J Thorac Cardiovasc Surg 31 (2007) 529-535
2. Rusch V.W. Mesothelioma and less common tumors. In: Pearson F.G., Cooper J.D., Deslauriers J., Ginsberg R.J., Patterson G.A., and Urschel H.C. (Eds). Thoracic surgery (2000), W.B. Saunders, Philadelphia
3. Flores R.M., Akhurst T., Gonen M., Zakowski M., Dycoco J., Larson S.M., and Rusch V.W. Positron emission tomography (PET) predicts survival in malignant pleural mesothelioma (MPM). J Thorac Cardiovasc Surg 132 (2006) 763-768
4. Rusch V.W., Rosenzweig K., Venkatraman E., Leon L., Raben A., Harrison L., Bains M.S., Downey R.J., and Ginsberg R.J. A Phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
5. Kruklitis R.J., Singhal S., Delong P., Kapoor V., Sterman D.H., Kaiser L.R., and Albelda S.M. Immuno-gene therapy with inteferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 127 (2004) 123-130
6. Mulatero C.W., Penson R.T., Papamichael D., Gower N.H., Evans M., and Rudd R.M. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 31 (2001) 67-72
7. Astoul P., Picat-Joossen D., Viallat J.-R., and Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. A phase II study. Cancer 83 (1998) 2099-2104
8. Broomfield S., Currie A., van der Most R.G., Brown M., van Bruggen I., Robinson B.W.S., and Lake R.A. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 65 (2005) 7580-7584
9. Rusch V.W., Saltz L., Venkatraman E., Ginsberg R., McCormack P., Burt M., Markman M., and Kelsen D. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12 (1994) 1156-1163
10. Richards W.G., Zellos L., Bueno R., Jaklitsch M.T., Jänne P.A., Chirieac L.R., Yeap B.Y., Dekkers R.J., Hartigan P.M., Capalbo L., and Sugarbaker D.J. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24 (2006) 1561-1567
11. Gupta V., Mychalczak B., Krug L., Flores R., Bains M., Rusch V.W., and Rosenzweig K.E. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 63 (2005) 1045-1052
12. Baldini E.H., Recht A., Strauss G.M., DeCamp Jr. M.M., Swanson S.J., Liptay M.J., Mentzer S.J., and Sugarbaker D.J. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 (1997) 334-338
13. Boutin C., Rey F., and Viallat J.-R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108 (1995) 754-758
14. Mattson K., Giaccone G., Kirkpatrick A., Evrard D., Tammilehto L., van Breukelen J.M., Planteydt H.T., and Van Zandwijk N. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10 (1992) 824-828
15. Flores R.M., Krug L.M., Rosenzweig K.E., Venkatraman E., Vincent A., Heelan R., Akhurst T., and Rusch V.W. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1 (2006) 289-295
16. Weder W., Kestenholz P., Taverna C., Bodis S., Lardinois D., Jerman M., and Stahel R.A. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 (2004) 3451-3457